Evaluation of the Antiproliferative Properties of CpRu Complexes Containing N-Methylated Triazaphosphaadamantane Derivatives.

IF 4.7 3区化学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioinorganic Chemistry and Applications Pub Date : 2023-09-28 eCollection Date: 2023-01-01 DOI:10.1155/2023/6669394

Andres Alguacil, Franco Scalambra, Antonio Romerosa, Andreia Bento-Oliveira, Fernanda Marques, Ines Maximiano, Rodrigo F M de Almeida, Ana Isabel Tomaz, Andreia Valente

{"title":"Evaluation of the Antiproliferative Properties of CpRu Complexes Containing N-Methylated Triazaphosphaadamantane Derivatives.","authors":"Andres Alguacil, Franco Scalambra, Antonio Romerosa, Andreia Bento-Oliveira, Fernanda Marques, Ines Maximiano, Rodrigo F M de Almeida, Ana Isabel Tomaz, Andreia Valente","doi":"10.1155/2023/6669394","DOIUrl":null,"url":null,"abstract":"Piano-stool-{CpRu} complexes containing 1,3,5-triaza-7-phosphaadamantane (PTA), N-methyl-1,3,5-triaza-7-phosphaadamantane (mPTA), and 3,7-dimethyl-1,3,7-triaza-5-phosphabyciclo[3.3.1]nonane (dmoPTA) were evaluated as drugs against breast cancer. The evaluated compounds include two new examples of this family, the complexes [RuCp(DMSO-κS)(HdmoPTA)(PPh3)](CF3SO3)2 (8) and [RuCp(PPh3)2-µ-dmoPTA-1κP-2κ2N,N′-PdCl2](CF3SO3) (11), which have been synthesized and characterized by NMR, IR, and single-crystal X-ray diffraction. The cytotoxic activity of compounds was evaluated against MDA-MB-231 breast cancer cells, and the three most active complexes were further tested against the hormone-dependent MCF-7 breast cancer cell line. Their cell death mechanism and ruthenium uptake were also evaluated, as well as their binding ability to human serum albumin.","PeriodicalId":8914,"journal":{"name":"Bioinorganic Chemistry and Applications","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555500/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioinorganic Chemistry and Applications","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1155/2023/6669394","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Piano-stool-{CpRu} complexes containing 1,3,5-triaza-7-phosphaadamantane (PTA), N-methyl-1,3,5-triaza-7-phosphaadamantane (mPTA), and 3,7-dimethyl-1,3,7-triaza-5-phosphabyciclo[3.3.1]nonane (dmoPTA) were evaluated as drugs against breast cancer. The evaluated compounds include two new examples of this family, the complexes [RuCp(DMSO-κS)(HdmoPTA)(PPh3)](CF3SO3)2 (8) and [RuCp(PPh3)2-µ-dmoPTA-1κP-2κ2N,N′-PdCl2](CF3SO3) (11), which have been synthesized and characterized by NMR, IR, and single-crystal X-ray diffraction. The cytotoxic activity of compounds was evaluated against MDA-MB-231 breast cancer cells, and the three most active complexes were further tested against the hormone-dependent MCF-7 breast cancer cell line. Their cell death mechanism and ruthenium uptake were also evaluated, as well as their binding ability to human serum albumin.

Abstract Image

查看原文本刊更多论文

含N-甲基三氮杂膦-金刚烷衍生物的CpRu配合物抗增殖性能的评价。

含有1,3,5-三氮杂-7-磷酰金刚烷（PTA）、N-甲基-1,3,5-三氮杂-7-磷酰氨基金刚烷（mPTA）和3,7-二甲基-1,3,7-三氮杂-5-磷酰氨基[3.3.1]壬烷（dmoPTA）的片粪-{CpRu}复合物被评估为抗癌症的药物。所评估的化合物包括该家族的两个新实例，复合物[RuCp（DMSO-κS）（HdmoPTA）（PPh3）]（CF3SO3）2（8）和[RuCp（PPh3）2-µ-dmoPTA-1κP-2κ2N，N'-PdCl2]（CF3SO3]）（11），它们已被合成并通过NMR、IR和单晶X射线衍射进行表征。评估了化合物对MDA-MB-231乳腺癌症细胞的细胞毒性活性，并进一步测试了三种最具活性的复合物对激素依赖性MCF-7乳腺癌症细胞系的细胞毒性。还评估了它们的细胞死亡机制和钌的摄取，以及它们与人血清白蛋白的结合能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioinorganic Chemistry and Applications 化学-生化与分子生物学

CiteScore

7.00

自引率

5.30%

发文量

105

审稿时长

>12 weeks

期刊介绍： Bioinorganic Chemistry and Applications is primarily devoted to original research papers, but also publishes review articles, editorials, and letter to the editor in the general field of bioinorganic chemistry and its applications. Its scope includes all aspects of bioinorganic chemistry, including bioorganometallic chemistry and applied bioinorganic chemistry. The journal welcomes papers relating to metalloenzymes and model compounds, metal-based drugs, biomaterials, biocatalysis and bioelectronics, metals in biology and medicine, metals toxicology and metals in the environment, metal interactions with biomolecules and spectroscopic applications.